Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piroctone olamine, marketed by Garonit Pharmaceutical under the trade name **PiroShield**, is a small molecule ethanolamine salt of the hydroxamic acid derivative piroctone. It is primarily utilized as an antifungal and antimicrobial agent in dermatological and personal care products, most notably in anti-dandruff shampoos. Its mechanism of action involves the chelation of polyvalent metal ions, such as iron (Fe3+) and copper (Cu2+), which disrupts mitochondrial activity and energy metabolism in fungi, particularly *Malassezia* species associated with dandruff and seborrheic dermatitis. Beyond its therapeutic applications, piroctone olamine is employed as a preservative in cosmetic formulations due to its broad-spectrum efficacy against bacteria, yeasts, and molds, offering a favorable safety and solubility profile compared to traditional agents like zinc pyrithione.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on piroctone olamine.